Medpace (MEDP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changi ...

West Pharmaceutical Services (WST) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by ...

Calix (CALX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The powe ...

Mitsubishi UFJ (MUFG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors o ...

HomeTrust Bancshares (HTB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the ...

Investors might want to bet on Third Coast Bancshares, Inc. (TCBX) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked ...

Investors might want to bet on IBM (IBM) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a changing earn ...

Key Takeaways HUM is expected to post Q2 EPS of $6.32 and revenues of $31.78B, with the latter indicating an 8.2% YoY rise.A 21.4% rise in Insurance unit income and strong premium growth may drive a positive Q2 earnings surprise.Higher costs, a 5.8% drop in insurance membership and lower investment income could pressure performance.Humana Inc. (HUM) is set to report second-quarter 2025 results on July 30, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is curr ...

Key Takeaways AbbVie will report Q2 earnings on July 31, with estimates at $15.07 billion for revenues and $2.89 for EPS.Skyrizi and Rinvoq are expected to drive growth, offsetting Humira sales erosion.Neuroscience sales strength contrasts with softness in aesthetics amid Botox and Juvederm slowdown.AbbVie (ABBV) is set to report second-quarter 2025 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $15.07 billion and $2.89 per share, ...

Key Takeaways Q2 EPS fell 37.9% YoY to $0.41 but beat estimates by 2.5%; revenues declined 7% to $1.37B.Talent Solutions revenues dropped 11.3%, while Protiviti rose 2% but missed internal projections.Gross margin declined 210 bps to 39.1%; Q3 EPS guidance of $0.37-$0.47 trails the consensus estimate.Robert Half International Inc. (RHI) reported impressive second-quarter fiscal 2026 results, wherein earnings and revenues beat the Zacks Consensus Estimate but failed to impress the market.The stock has moved ...